SE7500215L - - Google Patents
Info
- Publication number
- SE7500215L SE7500215L SE7500215A SE7500215A SE7500215L SE 7500215 L SE7500215 L SE 7500215L SE 7500215 A SE7500215 A SE 7500215A SE 7500215 A SE7500215 A SE 7500215A SE 7500215 L SE7500215 L SE 7500215L
- Authority
- SE
- Sweden
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/432,379 US4314081A (en) | 1974-01-10 | 1974-01-10 | Arloxyphenylpropylamines |
KR1019750000261A KR800001009B1 (ko) | 1975-01-09 | 1975-01-09 | 아릴옥시페닐프로필 아민류의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7500215L true SE7500215L (nl) | 1975-07-11 |
SE412906B SE412906B (sv) | 1980-03-24 |
Family
ID=26625843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7500215A SE412906B (sv) | 1974-01-10 | 1975-01-09 | Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan |
Country Status (23)
Country | Link |
---|---|
US (1) | US4314081A (nl) |
JP (1) | JPS5939418B2 (nl) |
AR (3) | AR205633A1 (nl) |
AT (1) | AT336000B (nl) |
BE (1) | BE824255A (nl) |
BG (3) | BG26192A3 (nl) |
CA (1) | CA1051034A (nl) |
CH (1) | CH609675A5 (nl) |
CS (1) | CS189680B2 (nl) |
DD (1) | DD118613A5 (nl) |
DE (1) | DE2500110A1 (nl) |
DK (1) | DK140430B (nl) |
ES (1) | ES433720A1 (nl) |
FR (1) | FR2257288B1 (nl) |
GB (1) | GB1493961A (nl) |
IE (1) | IE40346B1 (nl) |
NL (2) | NL181654C (nl) |
PH (1) | PH11652A (nl) |
RO (2) | RO69763A (nl) |
SE (1) | SE412906B (nl) |
SU (1) | SU1005655A3 (nl) |
YU (3) | YU36915B (nl) |
ZA (1) | ZA7532B (nl) |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4584404A (en) * | 1974-01-10 | 1986-04-22 | Eli Lilly And Company | Substituted phenoxyphenylproply dimethylamines |
JPS5283811A (en) * | 1976-01-01 | 1977-07-13 | Lilly Co Eli | Aryloxy phenyl propylamines and their salts |
GB1570613A (en) * | 1976-10-27 | 1980-07-02 | Akzo Nv | Biologically active tricyclic compounds and pharmaceutical compositions containing same |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
FR2455571A2 (fr) * | 1979-02-15 | 1980-11-28 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments |
DE3017812A1 (de) * | 1980-05-09 | 1981-11-12 | Merck Patent Gmbh, 6100 Darmstadt | Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
US4430319A (en) | 1982-05-21 | 1984-02-07 | State University Of New York | Radioactive iodine labeled phenolic amines |
US4692469A (en) * | 1982-09-07 | 1987-09-08 | Ciba-Geigy Corporation | Propylamine derivatives |
US4824868A (en) * | 1982-09-07 | 1989-04-25 | Ciba-Geigy Corporation | Propylamine derivatives useful for the treatment of dementia |
US4590213A (en) * | 1983-04-08 | 1986-05-20 | Eli Lilly And Company | Anti-anxiety method |
HU207282B (en) * | 1984-05-31 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them |
US4683235A (en) * | 1985-02-25 | 1987-07-28 | Eli Lilly And Company | Analgesic method |
US4594358A (en) * | 1985-02-25 | 1986-06-10 | Eli Lilly And Company | Analgesic method |
US4777291A (en) * | 1985-02-27 | 1988-10-11 | Eli Lilly And Company | Racemization process |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
US5135947A (en) * | 1987-04-09 | 1992-08-04 | Eli Lilly And Company | 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors |
CA1327795C (en) * | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
US5149714A (en) * | 1987-08-14 | 1992-09-22 | Merrell Dow Pharmaceuticals Inc. | Antidepressants |
US5223540A (en) * | 1987-10-22 | 1993-06-29 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
US4971998A (en) * | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4996235A (en) * | 1987-11-25 | 1991-02-26 | Eli Lilly And Company | 3,4-diphenylbutanamines |
US4876282A (en) * | 1987-11-25 | 1989-10-24 | Eli Lilly And Company | 1-Phenylalkylamines as selective serotonin uptake inhibitors |
US5238959A (en) * | 1988-04-08 | 1993-08-24 | Eli Lilly And Company | 3-phenyloxy-3-phenyl propanamines |
CA1337128C (en) * | 1988-04-08 | 1995-09-26 | David Wayne Robertson | Propanamine derivatives |
US5250571A (en) * | 1988-11-14 | 1993-10-05 | Eli Lilly And Company | (S)-norfluoxetine in method of inhibiting serotonin uptake |
US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
IT1228209B (it) * | 1989-01-10 | 1991-06-05 | Grato Magnone | Procedimento per la preparazione di fluoxetina cloridrato. |
FI81083C (fi) * | 1989-03-03 | 1990-09-10 | Orion Yhtymae Oy | Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid. |
US5166437A (en) * | 1989-03-03 | 1992-11-24 | Orion-Yhtyma Oy | Process for the preparation of fluoxetine |
DK258389D0 (da) * | 1989-05-26 | 1989-05-26 | Ferrosan As | Aryloxyphenylpropylaminer, deres fremstilling og anvendelse |
JPH0375680U (nl) * | 1989-11-21 | 1991-07-30 | ||
US5021426A (en) * | 1990-02-26 | 1991-06-04 | Merck & Co., Inc. | Method of traeting malaria with cyproheptadine derivatives |
US5356934A (en) * | 1990-03-29 | 1994-10-18 | Eli Lilly And Company | Selected serotonin subtype receptor agonist to treat sleep apnea |
US5250572A (en) * | 1990-03-29 | 1993-10-05 | Eli Lilly And Company | (R)-norfluoxetine in method for occupying serotonin IC receptors |
US5589511A (en) * | 1990-08-13 | 1996-12-31 | Sepracor Inc. | Method for treating migraine headaches using optically pure S(+) fluoxetine |
US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
AU642582B2 (en) * | 1991-02-25 | 1993-10-21 | Eli Lilly And Company | Treatment of lower urinary tract disorders |
US5136079A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Regioselective synthesis |
US5136078A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Synthesis of b-cyanohydrins |
US5320825A (en) * | 1991-05-01 | 1994-06-14 | Trustees Of The University Of Pennsylvania | Serotonin reuptake inhibitors for S.P.E.C.T. imaging |
WO1993000811A1 (en) * | 1991-07-01 | 1993-01-21 | The General Hospital Corporation | Invertebrate phenylethanolamine transporter and the use thereof |
IL99316A (en) * | 1991-08-27 | 1995-03-15 | Teva Pharma | Production of fluoxetine and new intermediates |
US5202319A (en) * | 1991-09-23 | 1993-04-13 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines |
DK0537915T3 (da) * | 1991-09-27 | 1995-11-27 | Lilly Co Eli | N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin |
US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
HU9202128D0 (en) * | 1992-06-26 | 1992-10-28 | Richter Gedeon Vegyeszet | Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine |
EP0576766A1 (en) * | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
US6017965A (en) * | 1993-02-08 | 2000-01-25 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US7087765B2 (en) * | 1995-06-07 | 2006-08-08 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
ES2101650B1 (es) * | 1995-06-29 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina. |
US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
ES2101654B1 (es) * | 1995-07-24 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina. |
ES2101655B1 (es) * | 1995-07-28 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina. |
ES2103680B1 (es) * | 1995-08-03 | 1998-04-01 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina. |
DE69607904T2 (de) * | 1995-08-16 | 2000-10-05 | Lilly Co Eli | Potenzierung von Serotonin-Wirkstoffresponz |
ES2103681B1 (es) * | 1995-09-19 | 1998-04-01 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina. |
IT1283141B1 (it) * | 1996-07-11 | 1998-04-07 | Laporte Organics Francis S P A | Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US5830500A (en) * | 1996-07-22 | 1998-11-03 | Pentech Pharmaceuticals, Inc. | Low dose fluoxetine tablet |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
IL135825A0 (en) * | 1997-11-14 | 2001-05-20 | Akzo Nobel Nv | Use of mirtazapine for treating sleep apneas |
US5936124A (en) * | 1998-06-22 | 1999-08-10 | Sepacor Inc. | Fluoxetine process from benzoylpropionic acid |
US6025517A (en) * | 1998-08-03 | 2000-02-15 | Sepracor Inc. | Fluoxetine process from benzoylacetonitrile |
AU2180400A (en) * | 1999-01-13 | 2000-08-01 | Eli Lilly And Company | A pharmaceutical combination for the treatment of depression |
FR2791345B1 (fr) * | 1999-03-26 | 2001-05-04 | Adir | Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU3219800A (en) * | 1999-03-29 | 2000-10-16 | Eli Lilly And Company | Stereospecific method for preparing tomoxetine and intermediates thereof |
IL148159A0 (en) * | 1999-09-03 | 2002-09-12 | Lilly Co Eli | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
AU1724201A (en) | 1999-12-17 | 2001-06-25 | Ranbaxy Laboratories Limited | Process for the preparation of fluoxetine hydrochloride |
GB0004151D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
GB0004149D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
GB0004153D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
GB0004152D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
US6273260B1 (en) | 2000-03-08 | 2001-08-14 | Eli Lilly And Company | Pharmaceutical packaging system |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
JP2003530437A (ja) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Aβ42低下物質 |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6316672B1 (en) | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
US6258853B1 (en) | 2001-01-31 | 2001-07-10 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
US6313350B1 (en) | 2001-01-31 | 2001-11-06 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
US6310250B1 (en) | 2001-01-31 | 2001-10-30 | Grayson Walker Stowell | Form A of fluoxetine hydrochloride |
US6310251B1 (en) | 2001-01-31 | 2001-10-30 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
AP2003002855A0 (en) * | 2001-03-06 | 2003-08-20 | Lilly Co Eli | Inhibitor of monoamine uptake. |
US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
AR035700A1 (es) * | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
US7034059B2 (en) * | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
JP2005500344A (ja) * | 2001-07-31 | 2005-01-06 | ファルマシア・アンド・アップジョン・カンパニー | 3−アリールオキシ−3−フェニルプロパンアミンを用いた慢性疼痛の治療 |
SE0102640D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
SE0102641D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
US20040170688A1 (en) * | 2001-08-06 | 2004-09-02 | Deshmukh Abhijit Mukund | Enteric formulation of fluoxetin |
WO2003013480A1 (en) | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
US6630454B2 (en) | 2001-09-10 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Method and pharmaceutical composition for the treatment of cancer |
MXPA04003358A (es) * | 2001-10-12 | 2004-07-08 | Serenix Pharmaceuticals Llc | Antagonistas de vasopresina v1a de ?-lactamilo. |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
DK1455770T3 (da) * | 2001-11-30 | 2007-10-08 | Lilly Co Eli | Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser |
EA200400793A1 (ru) * | 2001-12-11 | 2004-10-28 | Эли Лилли Энд Компани | Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции |
EP1490090A4 (en) | 2002-02-22 | 2006-09-20 | New River Pharmaceuticals Inc | SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS |
AU2003273281A1 (en) * | 2002-05-31 | 2003-12-19 | The Forsyth Institute | Methods for increasing bone density |
JP2004077714A (ja) * | 2002-08-15 | 2004-03-11 | Fuji Xerox Co Ltd | 光走査装置 |
SE0203304D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
US6846957B2 (en) * | 2002-11-22 | 2005-01-25 | Board Of Regents, The University Of Texas System | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor |
US20040235925A1 (en) * | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
WO2004091596A2 (en) * | 2003-04-18 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Combination therapies for chronic obstructive pulmonary disease (copd) |
CA2753318A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives |
US20050042284A1 (en) * | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
CN1849153A (zh) | 2003-09-12 | 2006-10-18 | 辉瑞大药厂 | 含有α-2-δ配体和5-羟色胺/去甲肾上腺素重摄取抑制剂的组合物 |
ATE420881T1 (de) * | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors |
JP4864719B2 (ja) * | 2003-11-26 | 2012-02-01 | ファイザー・プロダクツ・インク | Gsk−3インヒビターとしてのアミノピラゾール誘導体 |
PT1691811E (pt) | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
WO2005065673A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
EP1732610A2 (en) * | 2004-03-26 | 2006-12-20 | Baylor University | Targeted serotonin reuptake inhibitors |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
AU2005241023A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
EP1794112A4 (en) * | 2004-09-27 | 2009-11-04 | Reddys Lab Ltd Dr | SYNTHESIS OF ATOMEXETINE HYDROCHLORIDE |
JP2007523213A (ja) * | 2004-12-23 | 2007-08-16 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法 |
WO2006096809A1 (en) * | 2005-03-08 | 2006-09-14 | Teva Pharmaceutical Industries Ltd. | Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof |
CA2599478A1 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Process for the purification of duloxetine hydrochloride |
WO2006102308A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1b antagonists |
EP1871358A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists |
MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
JP2008538577A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ジヒドロベンゾフラン誘導体およびその使用 |
EP1879875A1 (en) * | 2005-04-22 | 2008-01-23 | Wyeth | Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
US7485754B2 (en) * | 2005-07-08 | 2009-02-03 | Apotex Pharmachem Inc. | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers |
NZ565683A (en) * | 2005-07-08 | 2011-04-29 | Braincells Inc | Methods for identifying agents and conditions that modulate neurogenesis in human neural cells |
US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
SI1910346T1 (sl) * | 2005-07-19 | 2019-08-30 | Azevan Pharmaceuticals, Inc. | Antagonist beta-laktamil fenilalalina, cisteina in serin vasopresina |
EA200800360A1 (ru) * | 2005-07-22 | 2008-06-30 | Мириад Дженетикс, Инк. | Формуляции с высоким содержанием лекарства и дозированные формы |
US7598255B2 (en) * | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US7842717B2 (en) * | 2005-09-22 | 2010-11-30 | Teva Pharmaceutical Industries Ltd. | DNT-maleate and methods of preparation thereof |
US20080207923A1 (en) * | 2005-09-22 | 2008-08-28 | Santiago Ini | Pure DNT-maleate and methods of preparation thereof |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
CN1304360C (zh) * | 2005-12-12 | 2007-03-14 | 天津大学 | N,n-二甲基-3-羟基-3-芳基丙胺的制备方法 |
EP1844034A1 (en) * | 2006-01-23 | 2007-10-17 | Teva Pharmaceutical Industries Ltd | Dnt-fumarate and methods of preparation thereof |
FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
WO2007104035A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20070238716A1 (en) * | 2006-03-14 | 2007-10-11 | Murthy Ayanampudi S R | Statin stabilizing dosage formulations |
US20070225279A1 (en) * | 2006-03-24 | 2007-09-27 | Wyeth | Therapeutic combinations for the treatment of depression |
WO2007134077A2 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
WO2007139984A2 (en) * | 2006-05-23 | 2007-12-06 | Teva Pharmaceutical Industries Ltd. | Duloxetine hcl polymorphs |
US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
WO2008010087A2 (en) * | 2006-07-14 | 2008-01-24 | Ranbaxy Laboratories Limited | Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof |
TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
WO2008026227A2 (en) * | 2006-08-28 | 2008-03-06 | Matrix Laboratories Ltd | A process for the preparation of atomoxetine hydrochloride |
MX2009002496A (es) * | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
WO2008034032A2 (en) * | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
EP2063905B1 (en) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
ITMI20061987A1 (it) * | 2006-10-16 | 2008-04-17 | Archimica Srl | Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine. |
WO2008062473A1 (en) * | 2006-10-31 | 2008-05-29 | Cadila Healthcare Limited | Process for preparing atomoxetine hydrochloride |
FR2910319B1 (fr) | 2006-12-20 | 2011-06-03 | Substipharm Dev | Formulations pharmaceutiques dispersibles contenant de la fluoxetine |
WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
ES2763873T3 (es) | 2007-06-21 | 2020-06-01 | Veroscience Llc | Método de tratamiento de trastornos metabólicos y depresión con agonistas del receptor de dopamina |
WO2009141833A2 (en) * | 2008-04-17 | 2009-11-26 | Ind-Swift Laboratories Limited | An improved process for synthesizing highly pure atomoxetine |
US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
HUE059078T2 (hu) | 2009-02-20 | 2022-10-28 | Enhanx Biopharm Inc | Glutation-alapú hatóanyagszállító rendszer |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
IL295075A (en) | 2009-05-06 | 2022-09-01 | Laboratory Skin Care Inc | Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them |
WO2011027359A2 (en) | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
EP2348120B1 (en) | 2009-12-30 | 2014-06-11 | Universität Wien | Enzymatic reduction of 1-phenylpropanone and derivatives thereof |
AU2011272738B2 (en) | 2010-07-01 | 2015-08-20 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
WO2012020418A1 (en) | 2010-08-12 | 2012-02-16 | Matrix Laboratories Ltd | Novel polymorphs of 4-hydroxy atomoxetine hydrochloride |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
BR112013023810A2 (pt) | 2011-03-17 | 2016-12-13 | Lupin Ltd | composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina |
WO2014021802A1 (en) | 2012-07-31 | 2014-02-06 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. | Use of fluoxetine for increasing meat and milk production |
EP2879516A1 (en) | 2012-07-31 | 2015-06-10 | Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. | Use of fluoxetine in animals |
WO2014046544A1 (en) | 2012-09-21 | 2014-03-27 | Aapa B.V. | Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators |
BR112016022575A2 (pt) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
CN105777706B (zh) * | 2014-12-25 | 2019-08-23 | 江苏恩华药业股份有限公司 | 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 |
CA3075759A1 (en) | 2017-09-15 | 2019-03-21 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating brain injury |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683742A (en) * | 1951-02-23 | 1954-07-13 | Searle & Co | Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives |
ES251290A1 (es) * | 1958-08-21 | 1960-04-01 | Parke Davis & Co | Un procedimiento para la producciën de alcohilaminas arilsustituidas |
US3132179A (en) * | 1959-08-27 | 1964-05-05 | Sterling Drug Inc | Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation |
US3253040A (en) * | 1962-12-10 | 1966-05-24 | Union Carbide Corp | Process for the production of primary 3-hydrocarbyloxypropylamines |
-
1974
- 1974-01-10 US US05/432,379 patent/US4314081A/en not_active Expired - Lifetime
- 1974-12-30 DK DK688974AA patent/DK140430B/da not_active IP Right Cessation
- 1974-12-30 RO RO7480996A patent/RO69763A/ro unknown
- 1974-12-30 RO RO7490077A patent/RO70660A/ro unknown
-
1975
- 1975-01-01 AR AR257198A patent/AR205633A1/es active
- 1975-01-01 AR AR259904A patent/AR205577A1/es active
- 1975-01-01 AR AR259905A patent/AR205578A1/es active
- 1975-01-02 CA CA217,287A patent/CA1051034A/en not_active Expired
- 1975-01-02 IE IE1/75A patent/IE40346B1/xx not_active IP Right Cessation
- 1975-01-02 ZA ZA00750032A patent/ZA7532B/xx unknown
- 1975-01-03 PH PH16672A patent/PH11652A/en unknown
- 1975-01-03 DE DE19752500110 patent/DE2500110A1/de active Granted
- 1975-01-07 CH CH10275A patent/CH609675A5/xx active Protection Beyond IP Right Term
- 1975-01-07 NL NLAANVRAGE7500186,A patent/NL181654C/nl active Protection Beyond IP Right Term
- 1975-01-08 CS CS75150A patent/CS189680B2/cs unknown
- 1975-01-08 AT AT10275A patent/AT336000B/de active Protection Beyond IP Right Term
- 1975-01-09 YU YU0032/75A patent/YU36915B/xx unknown
- 1975-01-09 FR FR7500543A patent/FR2257288B1/fr not_active Expired
- 1975-01-09 BG BG7528686A patent/BG26192A3/xx unknown
- 1975-01-09 GB GB898/75A patent/GB1493961A/en not_active Expired
- 1975-01-09 BG BG30202A patent/BG23212A3/xx unknown
- 1975-01-09 SU SU752101119A patent/SU1005655A3/ru active
- 1975-01-09 SE SE7500215A patent/SE412906B/xx active Protection Beyond IP Right Term
- 1975-01-09 BE BE1006387A patent/BE824255A/xx not_active IP Right Cessation
- 1975-01-10 DD DD183594A patent/DD118613A5/xx unknown
- 1975-01-10 ES ES433720A patent/ES433720A1/es not_active Expired
- 1975-01-10 JP JP50005888A patent/JPS5939418B2/ja not_active Expired
-
1981
- 1981-04-13 YU YU1215/81A patent/YU37308B/xx unknown
- 1981-05-13 YU YU1214/81A patent/YU37307B/xx unknown
-
1993
- 1993-06-29 NL NL930108C patent/NL930108I2/nl unknown
-
1994
- 1994-02-25 BG BG98576A patent/BG60761B2/bg unknown
Also Published As
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Application for supplementary protection certificate filed |
Free format text: 7500215 |
|
NUG | Patent has lapsed |
Ref document number: 7500215-4 Effective date: 19950210 Format of ref document f/p: F |
|
NUG | Patent has lapsed |
Ref document number: 7500215-4 Format of ref document f/p: F |
|
SPCG | Supplementary protection certificate granted |
Free format text: 9490183, 950905, EXPIRES: 20000109 |